Clinical Center Blood Bank

Clinical Center Blood Bank

The entity operating as "and Blood Institute" is the public-facing research identity of the Department of Transfusion Medicine at the National Institutes of Health Clinical Center in Bethesda, Maryland. Founded in 1953 alongside the Clinical Center itself, the unit provides all blood-component and transfusion-medicine services for the hospital's roughly 1,600 active clinical research protocols (per NIH, 2023). Harvey G. Klein, a hematologist who trained at Johns Hopkins and the University of Minnesota, has led the department since 1984, making it one of the longest continuously led research-transfusion operations in the United States. The institute's operational model combines a donor center, an immunohematology reference laboratory, a cellular-engineering lab, and a clinical apheresis unit under one roof. Asset-allocation logic does not apply here — but a capital-equivalent framework would include federally appropriated NIH intramural research budget, which for the Clinical Center exceeded $500 million in fiscal year 2023 (per NIH Budget Office, 2023). The Blood Institute supports clinical investigators across oncology, infectious disease, immunology, and hematology trials by manufacturing specialized blood products — irradiated, washed, HLA-matched, or pathogen-reduced — that standard community blood banks cannot supply. Geographic footprint centers on the 240-bed Bethesda campus but serves patients referred from all 50 states and over 60 countries through NIH's clinical protocols. Staffing and scale are defined by federal FTE allocations rather than commercial headcount disclosures. The Department of Transfusion Medicine collectively employs clinical pathologists, research nurses, apheresis specialists, and laboratory technologists. The institute operates no satellite offices but maintains a significant mobile-donor-unit program for platelet and granulocyte collections. Adjacent vehicles include the NIH Blood Bank donor-recruitment network and longstanding research collaborations with the American Red Cross, the Department of Defense, and the Biomedical Advanced Research and Development Authority (BARDA). February 2024: The Clinical Center opened a newly renovated apheresis suite designed to double throughput for cell-therapy collections, reflecting sustained NIH investment despite a broader period of Clinical Center reorganization (per NIH, February 2024). A structural differentiator: The Blood Institute is one of the only transfusion-medicine programs globally whose primary performance metric is not cost-per-unit or margin on blood products, but successful enrollment and safety monitoring in first-in-human and Phase I/II clinical trials. Because the Clinical Center does not bill patients for protocol-related care, the institute operates free of the payer-mix constraints and DRG-based reimbursement pressures that shape every community-hospital transfusion service — a regulatory and economic architecture that makes it an irreplaceable partner for academic investigators testing novel cellular immunotherapies and pathogen-reduction technologies.